article thumbnail

470% price increases

World of DTC Marketing

AbbVie has also raised the price of Imbruvica by 82% since launching the drug in 2013. For a patient taking 3 tablets daily, the annual net price of Imbruvica increased from $72,587 in 2013 to $115,533 in 2017 (the last year for which AbbVie provided the Committee data). billion in 2013—the year it separated from Abbott—to $16.1

article thumbnail

Sorry, the Inflation Bill won’t lower healthcare costs

World of DTC Marketing

A Journal of the American Medical Association ( JAMA ) study investigated how five key factors were associated with healthcare increases from 1996 to 2013: Service price and intensity Population growth Population aging Disease prevalence or incidence Medical service utilization. Finally, there are healthcare administrative costs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK authority asks for director ban for Alliance Pharma CEO

pharmaphorum

The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director. Between 2013 and 2017, the price of a 50-tablet pack of prochlorperazine increased from £6.49 million to about £7.5 million, according to the CMA.

Pharma 59
article thumbnail

Pharma R&D productivity dips, but efficiency gains give hope

Clarivate

Figure 1 illustrates the trend in the number of NMEs first launched onto the world market between 2013 and 2022. In fact, the number of NMEs has grown by 65% between 2013 and 2022. Looking at NMEs launched globally in 2022 paints a gloomy picture at first sight, with a 28% drop from 2021 to 2022.

Pharma 52
article thumbnail

Kyowa Kirin drops Nourianz follow-up KW-6356 for Parkinson’s

pharmaphorum

.” KW-6356 is a follow-up to Kyowa Kirin’s first-generation adenosine A2 antagonist Nourianz/Nouriast (istradefylline), which finally claimed FDA approval in 2019 as an add-on to levodopa in Parkinson’s after more than two decades of R&D and has been available in Japan since 2013. billion yen (around $68 million).

article thumbnail

Patents: a necessary evil?

European Pharmaceutical Review

2 Recently, the US Patent and Trademark Office (US PTO) reiterated the concern that patents have been “misused to inhibit and delay – for years and even decades – competition from generic drugs and biosimilars, denying Americans access to lower-cost drugs.” 23 April 2013. Santa Clara High Technology Law Journal. 29(3), article 2.

article thumbnail

Sales Gamification: A Vital Feature for Sales Reps

Toolyt

To enhance the extra zeal of motivation and the competitive edge, Gamification is the ideal process to win over your sales agents. Forbes in 2013 estimated that over 70% of the global 2000 companies’ List were recorded saying on a survey that they plan to use gamification for marketing and customer retention.

Sales 52